Investment
Features
FeesSafety
Academy
More
Pluang+

Compare The Coca-Cola Co K (KO) vs Mesoblast Limited (MESO) Price & Performance

The Coca-Cola Co KTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

The Coca-Cola Co K vs Mesoblast Limited — how do they compare? The Coca-Cola Co K trades at $82.07 (market cap $353.32B), while Mesoblast Limited trades at $16.36 (market cap $2.17B). The key difference: The Coca-Cola Co K is far larger — about 162.8× Mesoblast Limited's market cap, and The Coca-Cola Co K pays a 2.58% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

KOMESO
Market Cap
$353.32B$2.17B
Volume
14,630,257
Sector
Consumer StaplesTechnology
52-Week High
$84.92$20.96
52-Week Low
$65.67$12.88
Enterprise Value
$383.39B$2.17B
Dividend Yield
2.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

The Coca-Cola Co K

Coca-Cola (KO) trades at $82.08, up 0.64% on the day, with a bullish analyst consensus and strong earnings beats in recent quarters. The stock shows robust profitability with a 27.8% net margin and 45.8% ROE, though valuations like a P/E of 25.82 are elevated. Technicals are mixed with a bearish overall signal but support near $82. Recent news highlights institutional buying and stable demand trends ahead of Q2 earnings.

Outlook remains positive given consistent dividend growth, earnings outperformance, and a $90.67 price target. Risks include high debt levels and regional demand volatility. The stock offers stability for income investors but faces valuation pressures amid macroeconomic uncertainty.

Mesoblast Limited

MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.

Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About The Coca-Cola Co K

The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.

Read more on KO

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO